BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
NASDAQ · GLPG · USD
Stock price, earnings
Quote as of Jun 4, 2026, 03:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Galapagos N.V.’s quoted price sits in the lower half of its reported 52-week range, 25.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Galapagos N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Oct 30, 2024 | -$0.77-185.19% vs estimate | $65.64M-16.08% vs estimate |
|---|
| Q2 2024 | Aug 1, 2024 | $0.14+450.0% vs estimate | $94.12M+25.15% vs estimate |
|---|
THE ANALYST VIEW
24 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
$897.85+$6.09 (+0.68%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 16.3% below the high.
$16.78-$0.42 (-2.44%)
Ultragenyx Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$2.29-$0.07 (-2.97%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.11% below the high.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$1.11-$0.06 (-5.13%)
Spero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.96% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
$4.65-$0.07 (-1.48%)
Kyntra Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.17% below the high.
